Zydus Lifesciences has signed co-marketing agreements with Torrent Pharma and Lupin to expand access to its semaglutide injection in India for type 2 diabetes and chronic weight management.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Zydus-Torrent Agreement
Zydus Lifesciences and Torrent Pharmaceuticals have entered into a licensing and supply agreement to co-market semaglutide injection in India, expanding access to GLP-1 therapy for patients with type 2 diabetes and chronic weight management. Under the agreement, Zydus will manufacture and supply the product, while Torrent Pharma will receive semi-exclusive rights to commercialize it under its own brand across the country.
Zydus will market the therapy under the brands SEMAGLYN, MASHEMA, and ALTERME, while Torrent Pharma will commercialize the product under the brand SEMBOLIC. As part of the arrangement, Torrent will pay Zydus an upfront licensing fee.
The semaglutide formulation developed by Zydus is supplied as a 15 mg/3 ml injection in a prefilled cartridge, designed for administration through a reusable, patient-friendly pen device. The platform allows delivery of multiple dosing strengths through a single device, which may improve patient convenience, treatment adherence, and long-term compliance in chronic disease management.
Semaglutide, a GLP-1 receptor agonist, is indicated for adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise, either as monotherapy when metformin is unsuitable or in combination with other antidiabetic therapies. It is also used for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related comorbidities such as hypertension, diabetes, or dyslipidaemia.
The partnership combines Zydus’s product development and manufacturing capabilities with Torrent Pharma’s strong presence in chronic therapies and extensive field force in India, with the aim of improving patient access to advanced metabolic treatments.
Zydus-Lupin Agreement
In a separate collaboration announced earlier, Zydus also signed a licensing and supply agreement with Lupin Limited to co-market the same semaglutide injection in India, further expanding the drug’s commercial reach. Under this agreement, Lupin has received semi-exclusive rights to market the product under the brands Semanext and Livarise, while Zydus will continue to commercialize the therapy under its own brands SEMAGLYN, MASHEMA, and ALTERME.
As part of the Lupin partnership, the company will pay Zydus upfront licensing fees along with milestone payments tied to predefined commercial milestones. The collaboration combines Zydus’s development and manufacturing capabilities with Lupin’s broad commercial network and presence in the Indian diabetes market.
Company leadership highlighted that the collaboration aims to expand patient access to innovative GLP-1 therapies and strengthen treatment options for metabolic disorders such as diabetes and obesity in India.
Together, the agreements with Torrent Pharma and Lupin position Zydus to significantly broaden the availability of its semaglutide injection across India by leveraging the commercial reach and field infrastructure of two major pharmaceutical companies.
Reference
Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India, 18 March 2026, https://zyduslife.com/investor/admin/uploads/21/83/Zydus-and-Torrent-Pharma-sign-licensing-agreement-to-co-market-innovative-Semaglutide-Injection-in-India.pdf
Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India, 17 March 2026, https://zyduslife.com/investor/admin/uploads/21/83/Zydus-and-Lupin-sign-licensing-agreement-for-co-marketing-Semaglutide-Injection-in-India.pdf
About the Writer
Chikkula Pavan Kumar, PharmD is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.